FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 2, 2011, Pages 751-756

  Choi, Ji Woong ^a,c   Gardell, Shannon E ^a   Herr, Deron R ^a   Rivera, Richard ^a   Lee, Chang Wook ^a   Noguchi, Kyoko ^a   Teo, Siew Teng ^a,b   Yung, Yun C ^a,b   Lu, Melissa ^a   Kennedy, Grace ^a   Chun, Jerold ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Gachon University College of Medicine   (South Korea)

Author keywords

G protein coupled receptor; Knockout; Lysophospholipid; Neuroprotection

Indexed keywords

FINGOLIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; ASTROCYTOSIS; CELL FUNCTION; CELL LINEAGE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; GLIA; IMMUNOMODULATION; IN SITU HYBRIDIZATION; LYMPHOCYTE MIGRATION; MOUSE; MOUSE MUTANT; NERVE CELL; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ASTROCYTES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENE EXPRESSION REGULATION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOSINE;

ANIMALIA;

EID: 79551674537     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1014154108     Document Type: Article

References (48)

1. Steinman L (1996) Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system. Cell 85:299-302.
2. Cohen JA, et al. (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402-415.
3. Kappos L, et al. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387-401.
4. Brinkmann V, et al. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277:21453-21457.
5. Mandala S, et al. (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346-349. (Pubitemid 34303689)
6. Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S (2003) The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 554:189-193. (Pubitemid 37324838)
7. Ishii M, et al. (2009) Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 458:524-528.
8. Gräler MH, Goetzl EJ (2004) The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 18:551-553.
9. Oo ML, et al. (2007) Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 282:9082-9089.
10. Mullershausen F, et al. (2009) Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol 5:428-434.
11. Fujino M, et al. (2003) Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 305:70-77. (Pubitemid 36378136)
12. Webb M, et al. (2004) Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 153:108-121. (Pubitemid 38950933)
13. Matloubian M, et al. (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427:355-360. (Pubitemid 38133663)
14. Pappu R, et al. (2007) Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 316:295-298. (Pubitemid 46633109)
15. Schwab SR, Cyster JG (2007) Finding a way out: Lymphocyte egress from lymphoid organs. Nat Immunol 8:1295-1301.
16. Martin R (2010) Multiple sclerosis: Closing in on an oral treatment. Nature 464: 360-362.
17. Chun J, Hartung HP (2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33:91-101.
18. Ishii I, Fukushima N, Ye X, Chun J (2004) Lysophospholipid receptors: Signaling and biology. Annu Rev Biochem 73:321-354.
19. Foster CA, et al. (2007) Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: Consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 323:469-475.
20. Miron VE, Schubart A, Antel JP (2008) Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci 274:13-17.
21. Wheeler D, Bandaru VV, Calabresi PA, Nath A, Haughey NJ (2008) A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain 131:3092-3102.
22. Van Doorn R, et al. (2010) Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia 58:1465-1476.
23. Tronche F, et al. (1999) Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet 23:99-103. (Pubitemid 29418797)
24. Zhu Y, et al. (2001) Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev 15:859-876. (Pubitemid 32295067)
25. Cai J, et al. (2007) A crucial role for Olig2 in white matter astrocyte development. Development 134:1887-1899. (Pubitemid 46939234)
26. Malatesta P, et al. (2003) Neuronal or glial progeny: Regional differences in radial glia fate. Neuron 37:751-764. (Pubitemid 36288548)
27. Brinkmann V, Pinschewer DD, Feng L, Chen S (2001) FTY720: Altered lymphocyte traffic results in allograft protection. Transplantation 72:764-769. (Pubitemid 32879840)
28. Chae SS, Proia RL, Hla T (2004) Constitutive expression of the S1P1 receptor in adult tissues. Prostaglandins Other Lipid Mediat 73:141-150.
29. Liu CH, Hla T (1997) The mouse gene for the inducible G-protein-coupled receptor edg-1. Genomics 43:15-24.
30. Allen NJ, Barres BA (2005) Signaling between glia and neurons: Focus on synaptic plasticity. Curr Opin Neurobiol 15:542-548.
31. Palay S, Chan-Palay V (1974) Cerebellar Cortex (Springer, New York).
32. Han MH, et al. (2008) Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451:1076-1081.
33. Bignami A, Eng LF, Dahl D, Uyeda CT (1972) Localization of the glial fibrillary acidic protein in astrocytes by immunofluorescence. Brain Res 43:429-435.
34. Tani M, et al. (1996) In situ hybridization analysis of glial fibrillary acidic protein mRNA reveals evidence of biphasic astrocyte activation during acute experimental autoimmune encephalomyelitis. Am J Pathol 148:889-896.
35. Holley JE, Gveric D, Newcombe J, CuznerML, Gutowski NJ (2003) Astrocyte characterization in the multiple sclerosis glial scar. Neuropathol Appl Neurobiol 29:434-444. (Pubitemid 37222717)
36. Malmeström C, Haghighi S, Rosengren L, Andersen O, Lycke J (2003) Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 61:1720-1725.
37. Nair A, Frederick TJ, Miller SD (2008) Astrocytes in multiple sclerosis: A product of their environment. Cell Mol Life Sci 65:2702-2720.
38. Luo J, et al. (2007) Glia-dependent TGF-beta signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis. J Clin Invest 117:3306-3315.
39. Sorensen SD, et al. (2003) Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol Pharmacol 64:1199-1209.
40. Kimura A, et al. (2007) Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells 25: 115-124. (Pubitemid 46052981)
41. Lock C, et al. (2002) Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8:500-508.
42. Pan S, et al. (2006) A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol 13:1227-1234.
43. Schwab SR, et al. (2005) Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309:1735-1739.
44. Wu YP, Mizugishi K, Bektas M, Sandhoff R, Proia RL (2008) Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease. Hum Mol Genet 17:2257-2264.
45. Miller DH, Leary SM (2007) Primary-progressive multiple sclerosis. Lancet Neurol 6: 903-912.
46. Yu N, Lariosa-Willingham KD, Lin FF, Webb M, Rao TS (2004) Characterization of lysophosphatidic acid and sphingosine-1-phosphate-mediated signal transduction in rat cortical oligodendrocytes. Glia 45:17-27. (Pubitemid 38076224)
47. Tham CS, Lin FF, Rao TS, Yu N, Webb M (2003) Microglial activation state and lysophospholipid acid receptor expression. Int J Dev Neurosci 21:431-443.
48. Tedesco-Silva H, et al. (2004) FTY720, a novel immunomodulator: Efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 77:1826-1833.